Altanserin

From Wikipedia, the free encyclopedia

Altanserin
Systematic (IUPAC) name
3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-2-sulfanylidene-1H-quinazolin-4-one
Identifiers
CAS number 76330-71-7
ATC code  ?
PubChem 3033677
Chemical data
Formula C22H22FN3O2S 
Mol. mass 411.49[1]
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Altanserin is a compound that binds to the 5-HT2A receptor (serotonin 2A receptor). It is a yellowish solid.[1] Labeled with the isotope fluorine-18 it is used as a radioligand in positron emission tomography (PET) studies of the brain, i.e., studies of the serotonin-2A neuroreceptors. Besides human neuroimaging studies altanserin has also been used in the study of rats.[2][3]

An alternative for PET imaging the 5-HT2A receptor is the [11C]MDL 100,907 radioligand. Fluorine-18-altanserin and tritium-MDL 100,907 have shown very comparable binding.[4] Both altanserin and MDL 100,907 are 5-HT2A receptor antagonists.[4] [18F]-setoperone can also be used in PET.

An alternative SPECT radioligand is the [123I]-5-I-R91150 receptor antagonist.[5]

A rapid chemical synthesis of fluorine-18 and H-2 dual-labeled altanserin has been described.[6]

[edit] Human brain mapping studies with altanserin

As of 2007 altanserin is probably not used in clinical routine. However, there have been performed several research-based neuroimaging studies with the compound in humans since the 1990's.[7][8] Some of these studies have considered methodogical issues such as the reproducibility of the method[9][10] or whether to use constant infusion[11] or bolus-infusion[12] delivery of altanserin. Other studies have compared altanserin binding to subject variables such as age, personality trait and disease.

The altanserin PET scan shows high binding in neocortex. The cerebellum is often regarded as a region with no specific 5-HT2A binding and the brain region is used as a reference in some studies, even though an autoradiography study has found nonnegligible levels of 5-HT2A binding in the human cerebellum,[13] and another type of study have observed strong immunoreaction against 5-HT2A receptor protein in rat Purkinje cells.[14]

In the table below is an overview of the results of altanserin binding seen in human PET-studies. A consistent finding across altanserin studies has been that the binding decreases with age. This is in line with in vitro studies of the 5-HT2A receptor,[15] as well as PET studies with other radioligands that binds to the receptor.[16]

The result for recovered bulimia-type anorexia nervosa[17] is in line with a SPECT study of anorexia nervosa patients, that found a decrease in frontal, occipital and parietal cortices.[5] The results of PET studies of the 5-HT2A in depression has been mixed.[18]

Altanserin neuroimaging studies
What Result Reference
Sex Higher binding in men [19]
Neuroticism (NEO PI-R) Increase in frontolimbic region [20]
Tourette syndrome Increase [21]
Obsessive-compulsive disorder Increase in caudate nuclei [22]
(Recovered) bulimia-type anorexia nervosa Decrease in left subgenual cingulate, left parietal cortex and right occipital cortex [17]
Unipolar depression Decrease in a region in right hemisphere (posterolateral orbitofrontal cortex and the anterior insular cortex) [23]
Major depressive disorder Decrease in hippocampus [24]
Older depressed patients Decrease in hippocampus [25]
Borderline personality disorder Increase in hippocampus [26]
Schizophrenia No significant cortical difference, higher binding in caudate [27]
At-risk mental state Decrease [28] See also [29]
Age Decrease [30]
Age Decrease [31]
Age Decrease in cortical regions (except occipital), increase in cerebellum [32]
Mild cognitive impairment Decrease [33]
Alzheimer's disease Decrease [34]

[edit] See also

[edit] References

  1. ^ a b ABX, Altanserin, Radeberg, Germany.
  2. ^ Christian Lemaire, R. Cantineau, M. Guillaume, A. Plenevaux, Leon Christiaens (December 1991). "Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats". Journal of Nuclear Medicine 32: 2266–2277. PMID 1744713. 
  3. ^ F. Biver, F. Lotstra, M. Monclus, S. Dethy, P. Damhaut, D. Wikler, A. Luxen and S. Goldman (May 1997). "In vivo binding of [18F]altanserin to rat brain 5HT2 receptors: A film and electronic autoradiographic study". Nuclear Medicine and Biology 24 (4): 357–360. doi:10.1016/S0969-8051(97)00054-1. PMID 9257335. 
  4. ^ a b Heidi Kristiansen, Bettina Elfving, Per Plenge, Lars H. Pinborg, Nic Gillings & Gitte Moos Knudsen (December 2005). "Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907". Synapse 58 (4): 249–257. doi:10.1002/syn.20205. 
  5. ^ a b Kurt Audenaert, Koen Van Laere, Filip Dumont, Miriam Vervaet, Ingeborg Goethals, Guido Slegers, John Mertens, Cees van Heeringen, Rudi A. Dierckx. "Decreased 5-HT2A Receptor Binding in Patients with Anorexia Nervosa". Journal of Nuclear Medicine 44: 163–169. 
  6. ^ Ping-Zhong Tan, Ronald M. Baldwin, Tao Fu, Dennis S. Charney, Robert B. Innis (May 1999). "Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2a receptors". Journal of Labelled Compounds and Radiopharmaceuticals 42 (5): 457–467. doi:10.1002/(SICI)1099-1344(199905)42:5<457::AID-JLCR206>3.0.CO;2-0. 
  7. ^ Frangoise Biver, Serge Goldman, André Luxen, Michel Monclus, Manuel Forestini, Julien Mendlewicz and Françoise Lotstra (September 1994). "Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography". European Journal of Nuclear Medicine and Molecular Imaging 21 (9): 937–946. doi:10.1007/BF00238117. 
  8. ^ Sadzot B, Lemaire C, Maquet P, Salmon E, Plenevaux A, Degueldre C, Hermanne JP, Guillaume M, Cantineau R, Comar D, et al. (September 1995). "Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls". Journal of Cerebral Blood Flow and Metabolism 15 (5): 787–797. PMID 7673371. 
  9. ^ Gwenn S. Smith, Julie C. Price, Brian J. Lopresti, Yiyun Huang, Norman Simpson, Daniel Holt, N. Scott Mason, Carolyn Cidis Meltzer, Robert A. Sweet, Thomas Nichols, Donald Sashin, Chester A. Mathis (1998). "Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain". Synapse 30 (4): 380–392. doi:10.1002/(SICI)1098-2396(199812)30:4<380::AID-SYN5>3.0.CO;2-U. 
  10. ^ Steven Haugbøl, Lars H. Pinborg, Haroon M. Arfan, Vibe Frøkjær, Jacob Madsen, Tim B. Dyrby, Claus Svarer and Gitte M. Knudsen (June 2007). "Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach". European Journal of Nuclear Medicine and Molecular Imaging 34 (6): 910–915. doi:10.1007/s00259-006-0296-y. 
  11. ^ Christopher H. van Dyck, Ping-Zhong Tan, Ronald M. Baldwin, Louis A. Amici, Pradeep K. Garg, Chin K. Ng, Robert Soufer, Dennis S. Charney and Robert B. Innis. "PET Quantification of 5-HT2A Receptors in the Human Brain: A Constant Infusion Paradigm with [18FAltanserin]". The Journal of Nuclear Medicine 41 (2): 234–241. PMID 10688105. 
  12. ^ Lars H Pinborg, Karen H Adams, Claus Svarer, Søren Holm*, Steen G Hasselbalch, Steven Haugbøl, Jacob Madsen and Gitte M Knudsen (2003). "Quantification of 5-HT2A Receptors in the Human Brain Using [18FAltanserin-PET and the Bolus/Infusion Approach]". Journal of Cerebral Blood Flow & Metabolism 23: 985–996. doi:10.1097/01.WCB.0000074092.59115.23. 
  13. ^ Sharon L. Eastwood, Philip W. J. Burnet, Rebecca Gittins, Kate Baker, Paul J. Harrison (November 2001). "Expression of serotonin 5-HT2A receptors in the human cerebellum and alterations in schizophrenia". Synapse 42 (2): 104–114. doi:10.1002/syn.1106. 
  14. ^ Toru Maeshima, Fumihiro Shutoh, Shun Hamada, Kouji Senzaki, Kayoko Hamaguchi-Hamada, Ryuzo Ito, Nobuo Okado (August 1998). "Serotonin2A receptor-like immunoreactivity in rat cerebellar Purkinje cells". Neuroscience Letters 252: 72–74. doi:10.1016/S0304-3940(98)00546-1. PMID 9756362. 
  15. ^ Jan O. Marcusson, David G. Morgan, Bengt Winblad, Caleb E. Finch (October 1984). "Serotonin-2 binding sites in human frontal cortex and hippocampus. Selective loss of S-2A sites with age". Brain Research 311 (1): 51–56. doi:10.1016/0006-8993(84)91397-0. PMID 6488044. 
  16. ^ D. F. Wong, H. N. Wagner Jr, R. F. Dannals, J. M. Links, J. J. Frost, H. T. Ravert, A. A. Wilson, A. E. Rosenbaum, Albert Gjedde, K. H. Douglass, et al. (December 1984). "Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain". Science 226 (4681): 1393–1396. doi:10.1126/science.6334363. 
  17. ^ a b Ursula F. Bailer, Julie C. Price, Carolyn C. Meltzer, Chester A. Mathis, Guido K. Frank, Lisa Weissfeld, Claire W. McConaha, Shannan E. Henry, Sarah Brooks-Achenbach, Nicole C. Barbarich, and Walter H. Kaye (2004). "Altered 5-HT2A receptor binding after recovery from bulimia-type anorexia nervosa: Relationships to harm avoidance and drive for thinness.". Neuropsychopharmacology 29: 1143–1155. doi:10.1038/sj.npp.1300430. 
  18. ^ Masahiro Fujita, Dennis S. Charneya, c and Robert B. Innis (October 2000). "Imaging serotonergic neurotransmission in depression: hippocampal pathophysiology may mirror global brain alterations". Biological Psychiatry 48 (8): 801–812. doi:10.1016/S0006-3223(00)00960-4. 
  19. ^ Françoise Biver, Françoise Lotstra, Michel Monclus, David Wikler, Philippe Damhaut, Julien Mendlewicz and Serge Goldman (February 1996). "Sex difference in 5HT2 receptor in the living human brain". Neuroscience Letters 204: 25–28. doi:10.1016/0304-3940(96)12307-7. PMID 8929969. 
  20. ^ Vibe G. Frøkjær, Erik Lykke Mortensen, Finn Årup Nielsen, Steven Haugbøl, Lars H Pinborg, Karen H. Adams, Claus Svarer, Steen G. Hasselbalch, Søren Holm, Olaf B. Paulson, Gitte Moos Knudsen (2008). "Frontolimbic Serotonin 2A Receptor Binding in Healthy Subjects Is Associated with Personality Risk Factors for Affective Disorder". Biological Psychiatry 63: 569. doi:10.1016/j.biopsych.2007.07.009. PMID 17884017. 
  21. ^ Steven Haugbøl, Lars H. Pinborg, Lisbeth Regeur, Elsebet S. Hansen, Tom G. Bolwig, Finn Årup Nielsen, Claus Svarer, Lene T. Skovgaardand Gitte M. Knudsen (2008). "Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome". The International Journal of Neuropsychopharmacology 63: 569. doi:10.1017/S1461145706006559. 
  22. ^ K. H. Adams, E. S. Hansen, L. H. Pinborg, S. G. Hasselbalch, C. Svarer, S. Holm, Tom G. Bolvig & Gitte Moos Knudsen (September 2005). "Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei". International Journal of Neuropsychopharmacology 8 (3): 391–401. doi:10.1017/S1461145705005055. PMID 15801987. 
  23. ^ F. Biver, D. Wikler, F. Lotstra, P. Damhaut, S. Goldman, J. Mendlewicz (November 1997). "Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex". British Journal of Psychiatry 171: 444–448. PMID 9463603. 
  24. ^ Mark A. Mintun, Yvette I. Sheline, Stephen M. Moerlein, Andrei G. Vlassenko, Yiyun Huang and Abraham Z. Snyder (February 2004). "Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography". Biological Psychiatry 55 (3): 217–224. doi:10.1016/j.biopsych.2003.08.015. 
  25. ^ Yvette I. Sheline, Mark A Mintun, Deanna M. Barch, Consuelo Wilkins, Abraham Z. Snyder & Stephen M. Moerlein (December 2004). "Decreased hippocampal 5-HT2A receptor binding in older depressed patients using [18Faltanserin positron emission tomography]". Neuropsychopharmacology 29 (12): 2235–2241. doi:10.1038/sj.npp.1300555. 
  26. ^ P. Soloff, J. Price, C. Meltzer, A. Fabio, G. Frank, W. Kaye (2007). "5HT2A Receptor Binding is Increased in Borderline Personality Disorder". Biological Psychiatry 62 (6): 580–587. doi:10.1016/j.biopsych.2006.10.022. 
  27. ^ David Erritzoe, Hans Rasmussen, Klaus T. Kristiansen, Vibe G. Frøkjær, Steven Haugbøl, Lars Pinborg, William Baaré, Claus Svarer, Jacob Madsen, Henrik Lublin, Gitte Moos Knudsen & Birte Y. Glenthøj (February 2008). "Cortical and Subcortical 5-HT2A Receptor Binding in Neuroleptic-Naive First-Episode Schizophrenic Patients". Neuropsychopharmacology 62: 580. doi:10.1038/sj.npp.1301656. PMID 18288096.  Electronic publication ahead of print
  28. ^ René Hurlemann, Andreas Matusch, Kai-Uwe Kuhn, Julia Berning, David Elmenhorst, Oliver Winz, Heike Kolsch, Karl Zilles, Michael Wagner, Wolfgang Maier and Andreas Bauer (January 2008). "5-HT2A receptor density is decreased in the at-risk mental state". Psychopharmacology 195 (4): 579–590. doi:10.1007/s00213-007-0921-x. PMID 17899021. 
  29. ^ René Hurlemann, Christian Boy, Philipp T. Meyer, Harald Scherk, Michael Wagner, Hans Herzog, Heinz H. Coenen, Kai Vogeley, Peter Falkai, Karl Zilles, Wolfgang Maier and Andreas Bauer (December 2005). "Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia". Anatomy and Embryology 210 (5-6): 519–523. doi:10.1007/s00429-005-0036-2. PMID 16187138. 
  30. ^ A. Rosier, P. Dupont, J. Peuskens, G. Bormans, R. Vandenberghe, M. Maes, T. de Groot, C. Schiepers, A. Verbruggen, L. Mortelmans (November 1996). "Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging". Psychiatry Research 68 (1): 11–22. doi:10.1016/S0925-4927(96)02806-5. PMID 9027929. 
  31. ^ Carolyn Cidis Meltzer, Gwenn Smith, Julie C. Price, Charles F. Reynolds III, Chester A. Mathis, , Phil Greer, Brian Lopresti, Mark A. Mintun, Bruce G. Pollock, Doron Ben-Eliezer, Michael N. Cantwell, Walter Kaye and Steven T. DeKosky (November 1998). "Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction". Brain Research 813 (1): 167–171. doi:10.1016/S0006-8993(98)00909-3. 
  32. ^ K. H. Adams, Lars H. Pinborg, Claus Svarer, S. G. Hasselbalch, Søren Holm, S. Haugbøl, K. Madsen, Vibe G. Frøkjaer, L. Martiny, Olaf B. Paulson, Gitte Moos Knudsen (March 2004). "A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables". Neuroimage 21 (3): 1105–1113. doi:10.1016/j.neuroimage.2003.10.046. PMID 15006678. 
  33. ^ Hasselbalch SG, Madsen K, Svarer C, Pinborg LH, Holm S, Olaf B. Paulson, Waldemar G, Gitte Moos Knudsen (2007). "Reduced 5-HT2A receptor binding in patients with mild cognitive impairment". Neurobiology of Aging. doi:10.1016/j.neurobiolaging.2007.04.011. PMID 17544547. 
  34. ^ Carolyn Cidis Meltzer, Julie C. Price, Chester A. Mathis, Phil J. Greer, Michael N. Cantwell, Patricia R. Houck, Benoit H. Mulsant, Doron Ben-Eliezer, Brian Lopresti, Steven T. DeKosky, and Charles F. Reynolds, III (December 1999). "PET Imaging of Serotonin Type 2A Receptors in Late-Life Neuropsychiatric Disorders". The American Journal of Psychiatry 156: 1871–1878. PMID 10588399. 


Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.